What is claimed is:

1. A pharmaceutical formulation comprising: (i) a human antibody that specifically binds to human nerve growth factor (hNGF); (ii) a non-ionic surfactant; and (iii) a carbohydrate.

2. The pharmaceutical formulation of claim 1, wherein the carbohydrate is a sugar.

3. The pharmaceutical formulation of claim 2, wherein the sugar is selected from the group consisting of sucrose, glucose, mannitol, sorbitol, lactose and trehalose.

4. The pharmaceutical formulation of claim 3, wherein the sugar is sucrose.

5. The pharmaceutical formulation of claim 1, wherein the non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80 and polyoxyethylene sorbitan monooleate.

6. The pharmaceutical formulation of claim 5, wherein the non-ionic surfactant is polysorbate 20.

7. The pharmaceutical formulation of claim 6, further comprising at least one amino acid selected from the group consisting of histidine or arginine.

8. The pharmaceutical formulation of any of claims 1-7, further comprising about 1 mM to about 50 mM acetate.

9. A pharmaceutical formulation comprising: (i) about 0.1 to 100 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.01 to 1.0 % of polysorbate 20; and (iii) about 1 to 20% sucrose.

10. The pharmaceutical formulation of claim 9 comprising: (i) about 0.2 to 75 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.02 to 0.5% polysorbate 20; and (iii) about 5 to 10% sucrose.

11. The pharmaceutical formulation of claim 10, comprising: (i) about 0.6-60 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.05% polysorbate 20; and (iii) about 8% sucrose.

12. The pharmaceutical formulation of any of claims 8-10, further comprising about 1.0 mM to about 50 mM acetate.

13. The pharmaceutical formulation of claim 12, contained in a glass vial or syringe, or a plastic vial or syringe.

14. The formulation of claim 13, wherein the glass vial is a silicon dioxide coated glass vial.

15. The formulation of claim 14, wherein the headspace in the glass vial is filled with an inert gas to remove oxygen.

16. The formulation of claim 15, wherein the inert gas is argon or nitrogen.

17. The pharmaceutical formulation of either one of claim 8 or 12, contained in an autoinjector or microinfusor.

18. The pharmaceutical formulation of claim 13, wherein the syringe comprises a fluorocarbon-coated plunger.

19. The pharmaceutical formulation of claim 18, wherein the syringe is a low tungsten syringe.

20. The pharmaceutical formulation of claim 19, wherein the syringe comprises a fluorocarbon-coated plunger.

21. The pharmaceutical formulation of any of claims 1-20, wherein the human antibody that specifically binds to hNGF comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises heavy chain complementarity determining regions comprising the amino acid sequences of SEQ ID NOs:6, 8, and 10, and wherein the LCVR comprises light chain complementarity determining regions comprising the amino acid sequences of SEQ ID NOs:14, 16 and 18.

22. The pharmaceutical formulation of claim 21, wherein the human antibody that specifically binds to hNGF comprises heavy chain and light chain variable region (HCVR / LCVR) amino acid sequence pairs selected from the group consisting of: (i) SEQ ID NOs:20/22; and (ii) SEQ ID NOs:4/12.

23. A pharmaceutical formulation comprising: (i) about 0.1-100 mg/mL of a human antibody that specifically binds to hNGF, wherein said antibody comprises a heavy chain and light chain variable region (HCVR / LCVR) amino acid sequence pair of SEQ ID NOs:20/22; (ii) about 0.05% polysorbate 20; (iii) about 8% sucrose; and (iv) about 10 mM acetate.

24. The pharmaceutical formulation of any of claims 1- 23, wherein the pH of the formulation ranges from about 4.5 to 5.6.

25. The pharmaceutical formulation of claim 24, wherein the pH of the formulation is 5.0.

26. The pharmaceutical formulation of any of claims 1-25, wherein the formulation is administered intravenously or subcutaneously.

27. The use of the pharmaceutical formulation of any of claims 1-26 in the preparation of a medicament for the treatment, prevention and/or amelioration of any disease or disorder associated with NGF activity or NGF activation.

What is claimed is:

1. A pharmaceutical formulation comprising:

(i) about 0.1 to 100 mg/ml of a human antibody that specifically binds to human nerve growth factor (hNGF), wherein the antibody comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pairs selected from the group consisting of: (a) SEQ ID NOs: 20/22; and (b) SEQ ID NOs 4/12;

(ii) about 0.01 to 1.0% of a polysorbate 20;

(iii) about 1 to 20% of sucrose; and

(iv) about 1 mM to about 50 mM acetate,

wherein 90% or more of the antibody is detected by size-exclusion-high-performance liquid chromatography (SE-HPLC) when stored at 5°C for six months.

2. The pharmaceutical formulation of claim 1, further comprising at least one amino acid selected from the group consisting of histidine or arginine.

3. The pharmaceutical formulation of claim 1 comprising: (i) about 0.2 to 75 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.02 to 0.5% polysorbate 20; and (iii) about 5 to 10% sucrose.

4. The pharmaceutical formulation of claim 3, comprising: (i) about 0.6-60 mg/mL of a human antibody that specifically binds to hNGF; (ii) about 0.5% polysorbate 20; and (iii) about 8% sucrose.

5. The pharmaceutical formulation of claim 1, further comprising:

a glass container selected from the group consisting of a glass vial, a glass syringe, a plastic vial, and a plastic syringe.

6. The formulation of claim 5, wherein the container is a glass vial comprising a silicon dioxide coated glass.

7. The formulation of claim 6, wherein the glass vial is filled with the formulation leaving headspace filled with an inert gas.

8. The formulation of claim 7, wherein the inert gas is selected from the group consisting of argon and nitrogen.

9. The pharmaceutical formulation of claim 1, further comprising:

a container selected from the group consisting of an autoinjector, and a microinfusor.

10. The pharmaceutical formulation of claim 5, wherein the glass container is the syringe and the syringe is a syringe comprising a fluorocarbon-coated plunger.

11. The pharmaceutical formulation of claim 10, wherein the syringe is a low tungsten syringe.

12. The pharmaceutical formulation of claim 11, wherein the syringe comprises a fluorocarbon-coated plunger.

13. A pharmaceutical formulation comprising:

(i) about 0.1-100 mg/mL of a human antibody that specifically binds to human nerve growth factor (hNGF);

(ii) about 0.05% polysorbate 20;

(iii) about 8% sucrose; and

(iv) about 10 mM acetate,

wherein said antibody comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pairs selected from the group consisting of: (a) SEQ ID NOs:20/22; and (b) SEQ ID NOs 4/12,

wherein 90% or more of the antibody is detected by size-exclusion-high-performance liquid chromatography (SE-HPLC) when stored at 5°C for six months.

14. The pharmaceutical formulation of claim 13, wherein the pH of the formulation ranges from about 4.5 to 5.6.

15. The pharmaceutical formulation of claim 14, wherein the pH of the formulation is 5.0.

16. The pharmaceutical formulation of claim 13, further comprising:

a glass container selected from the group consisting of a glass vial, a glass syringe, a plastic vial, and a plastic syringe.

17. The formulation of claim 16, wherein the container is a glass vial comprising a silicon dioxide coated glass.

18. The formulation of claim 17, wherein the glass vial is filled with the formulation leaving headspace filled with an inert gas.

19. The formulation of claim 18, wherein the inert gas is selected from the group consisting of argon and nitrogen.

20. The pharmaceutical formulation of claim 13, further comprising:
a container selected from the group consisting of an autoinjector, and a microinfusor.

21. The pharmaceutical formulation of claim 16, wherein the glass container is the syringe and the syringe is a syringe comprising a fluorocarbon-coated plunger.

22. The pharmaceutical formulation of claim 21, wherein the syringe is a low tungsten syringe.

23. The pharmaceutical formulation of claim 22, wherein the syringe comprises a fluorocarbon-coated plunger.

24. The pharmaceutical formulation of claim 1 or 13, wherein 95% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.

25. The pharmaceutical formulation of claim 1 or 13, wherein 96% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.

26. The pharmaceutical formulation of claim 1 or 13, wherein 97% or more of the antibody is detected by SE-HPLC when stored at 5°C for six months.